Nyrada Inc. (ASX:NYR) has dosed and discharged the first cohort of its Phase I human clinical trial of its lead drug candidate, NYR-BI03, according to a Monday filing with the Australian bourse.
The primary endpoint of the trial is to assess the safety and tolerability of NYR-BI03 in healthy volunteers, when administered as a three-hour intravenous infusion, per the filing.
Six participants received NYR-BI03, while two others received a placebo. Readouts from the trial are expected in the third quarter.
NYR-BI03 is a small molecule, first-in-class neuroprotection, and cardioprotection treatment.
Nyrada's shares were down 2% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.